Sugarman-Brozan says FDA is neglecting enforcement

Prescription Access Litigation project director Alex Sugarman-Brozan told the Third Annual FDA Regulatory Symposium at Harvard in August that the agency is neglecting to enforce regulations on DTC advertising and needs to crack down on drug companies with more and earlier enforcement letters and hefty fines on offending companies, per pending regs.

You must be a registered member of MMM to post a comment.
close

Next Article in Pharmaceutical

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.